Approximately one-third of patients are diagnosed with idiopathic pulmonary fibrosis (IPF) in Japan either during a routine health checkup or while undergoing an examination for another disease, while experiencing minimal or no respiratory symptoms, according to a new study published in Respiratory Medicine. In spite of being diagnosed at a relatively early stage of disease,…
Drugs targeting cyclin-dependent kinase (CDK) 4 and CDK6 can suppress the growth and survival of neoplastic mast cells, a new study published in Cancers found. Therefore, CDK4/CDK6 inhibitors could have curative potential in advanced systemic mastocytosis (SM), which is often resistant to drug treatment. The neoplastic mast cells, which are the hallmark of advanced SM,…
SH2 superbinder has significant antifibrotic effects, according to a new study published in Theranostics. The protein could therefore be used as a promising therapy for idiopathic pulmonary fibrosis (IPF), the authors of the study said. There is currently no effective treatment for IPF, so it is of great importance to developing new and better treatments…
Researchers discovered that compounds targeting cyclin-dependent kinase (CDK) 4 and CDK6 suppressed the neoplastic mast cell (MC) growth found in systemic mastocytosis (SM) and published their results in Cancers. They noted that it remains to be determined whether combinations of CDK4/CDK6 inhibitors and KIT D816-targeting drugs would be able to induce remission in patients with…
A randomized, double-blind, placebo-controlled phase 2b study was terminated due to adverse events (AEs) and a lack of efficacy of BG00011, an anti-αvβ6 immunoglobulin G1 monoclonal antibody, as therapy for idiopathic pulmonary fibrosis (IPF), according to a study published in the American Journal of Respiratory and Critical Care Medicine. The study was carried out after…
Researchers discovered that patients with idiopathic pulmonary fibrosis (IPF) tend to have multiple comorbidities, which is associated with poorer survival, even in patients receiving antifibrotic therapy, as published in Respiratory Research. Patients with IPF often struggle with a high disease burden and experience pulmonary and extrapulmonary comorbidities. These commodities can be caused by risk factors…
Cudetaxestat is well tolerated and leads to no treatment-related serious adverse events when coadministered with pirfenidone or nintedanib in healthy volunteers, according to the results of a phase 1 clinical trial. There were also no drug-drug interactions with cudetaxestat plus pirfenidone or nintedanib. These results were presented at the American Thoracic Society 2022 International Conference.…
Researchers have discovered that radiomic features can be used to predict the therapeutic response of patients with idiopathic pulmonary fibrosis (IPF) to antifibrotic agents, as published in Diagnostics. IPF causes excessive fibrotic deposition in the lung parenchyma, eventually resulting in respiratory failure. This disease carries a poor prognosis, with mortality usually occurring within 5 years…
The requirements for a phase 2 PoC/dose-ranging study of cudetaxestat for patients with idiopathic pulmonary fibrosis (IPF) have been outlined by the US Food and Drug Administration (FDA), according to a press release by Blade Therapeutics. Pending preclinical toxicity studies, the company will carry out the trial in the second quarter of 2022. “Taking a…
Pirfenidone and nintedanib target transforming growth factor-beta 1 (TGFβ1) signaling and mediate antifibrotic effects in idiopathic pulmonary fibrosis (IPF), according to a new study published in Scientific Reports. “We used an agnostic approach to identify markers of early TGFβ1-induced fibrogenesis and found TGFβ1 induced genes annotated as associated with pirfenidone and nintedanib treatment,” the authors…
